LuHui Derivative, A Novel Compound That Inhibits the Fat Mass and Obesity-Associated (FTO), Alleviates the Inflammatory Response and Injury in Hyperlipidemia-Induced Cardiomyopathy
Hyperlipidemia is a major risk factor for metabolic disorders and cardiovascular injury. The excessive deposition of saturated fatty acids in the heart leads to chronic cardiac inflammation, which in turn causes myocardial damage and systolic dysfunction. However, the effective suppression of cardia...
Guardado en:
Autores principales: | Ying Yu, Yumiao Pan, Ziyi Fan, Silun Xu, Zhiyuan Gao, Zijing Ren, Jie Yu, Wen Li, Fangtong Liu, Jintao Gu, Ye Yuan, Zhimin Du |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0b5983ffb2e04518a5e1ee71e86c44e2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ethyl 2-Succinate-Anthraquinone Attenuates Inflammatory Response and Oxidative Stress via Regulating NLRP3 Signaling Pathway
por: Burong Feng, et al.
Publicado: (2021) -
ECONOMIC ISSUES OF HUI REFORMING: AN AUDITOR VIEW
por: N. A. Haritonova
Publicado: (2015) -
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Peter Frøhlich Staanum, et al.
Publicado: (2021) -
IMPROVING THE EXISTING SYSTEM OF HUI FINANCING
por: A. N. Ryahovskaya, et al.
Publicado: (2015) -
Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Matthew Glover, et al.
Publicado: (2021)